These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38039875)

  • 21. Durvalumab with or without tremelimumab for patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a systematic review and meta-analysis.
    Han X; Zhang H; Sun K; Li J; Wu W; Liu K; Yu Z
    Front Immunol; 2023; 14():1302840. PubMed ID: 38299153
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.
    Liu L; Xiang Z; Li Y; Guo W; Yang K; Wang J; Sun Z; Ren G; Zhang J; Sun M; Ran W; Huang G; Tang Z; Li L
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):619-628. PubMed ID: 36416313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Optimal Second-Line Systemic Treatment Model for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: A Bayesian Network Meta-Analysis.
    Zhan ZJ; Yao WY; Zhang F; Qiu WZ; Liao K; Feng JH; Tan JY; Liu H; Yuan TZ; Zheng RH; Yuan YW
    Front Immunol; 2021; 12():719650. PubMed ID: 34413862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis.
    Tang L; Liu T; Chen J; Dang J; Li G
    Immunotherapy; 2021 Apr; 13(6):541-555. PubMed ID: 33629592
    [No Abstract]   [Full Text] [Related]  

  • 25. Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.
    Green SE; McCusker MG; Mehra R
    Expert Opin Emerg Drugs; 2020 Dec; 25(4):501-514. PubMed ID: 33196319
    [No Abstract]   [Full Text] [Related]  

  • 26. The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-Analysis.
    Ciccarese C; Iacovelli R; Bria E; Palazzo A; Maiorano BA; Mosillo C; Carbone C; Piro G; Tortora G
    J Immunother; 2020 Apr; 43(3):95-103. PubMed ID: 32080018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The primary site of head and neck squamous cell carcinoma predicts survival benefits of EGFR inhibitors: A systematic review and meta-analysis.
    Nie D; Wang X; Sun M; Feng Z; Pei F; Liu W; Wang Z; Han F
    Radiother Oncol; 2021 May; 158():13-20. PubMed ID: 33587969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and Survival After Immune Checkpoint Inhibition for Head and Neck Squamous Cell Carcinoma.
    Mastrolonardo EV; Llerena P; Lu J; Nunes K; Choi GK; Amin D; Bridgham KM; Campbell D; Philips R; Cognetti DM; Luginbuhl AJ; Curry JM
    JAMA Otolaryngol Head Neck Surg; 2024 Aug; 150(8):688-694. PubMed ID: 38958948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort.
    Issa M; Klamer BG; Mladkova N; Laliotis GI; Karivedu V; Bhateja P; Byington C; Dibs K; Pan X; Chakravarti A; Grecula J; Jhawar SR; Mitchell D; Baliga S; Old M; Carrau RL; Rocco JW; Blakaj DM; Bonomi M
    BMC Cancer; 2022 Jul; 22(1):767. PubMed ID: 35836204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chairoungdua A; Dajsakdipon T; Jiarpinitnun C
    Oral Oncol; 2023 Oct; 145():106520. PubMed ID: 37467684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of immune checkpoint inhibitors in elderly patients (≥70 years) with squamous cell carcinoma of the head and neck.
    Saleh K; Auperin A; Martin N; Borcoman E; Torossian N; Iacob M; Ferrand FR; Khalife N; Baste N; Guigay J; Le Tourneau C; Daste A; Saada-Bouzid E; Even C
    Eur J Cancer; 2021 Nov; 157():190-197. PubMed ID: 34536943
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-1/PD-L1 inhibitor plus chemotherapy versus standard of care in the first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma.
    Mo DC; Huang JF; Luo PH; Chen L; Zou B; Wang HL
    Eur Arch Otorhinolaryngol; 2023 Jan; 280(1):1-9. PubMed ID: 35907001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
    Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
    Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Miyamoto N; Takenaka Y; Sudo T; Eguchi H; Tanaka H; Fukusumi T; Takemoto N; Suzuki M; Inohara H
    Acta Otolaryngol; 2023 Oct; 143(10):925-930. PubMed ID: 38059478
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of PD-1/PD-L1 checkpoint inhibitors on recurrent/metastatic head and neck squamous cell carcinoma: a critical review of the literature and meta-analysis.
    Clarke E; Eriksen JG; Barrett S
    Acta Oncol; 2021 Nov; 60(11):1534-1542. PubMed ID: 34410881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-1/PD-L1 inhibitor monotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck: a meta-analysis.
    Chen L; Mo DC; Hu M; Zhao SJ; Yang QW; Huang ZL
    Am J Otolaryngol; 2022; 43(2):103324. PubMed ID: 34923281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of systemic treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis.
    Wang H; Zhao Q; Zhang Y; Wei J; Wang B; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Pharmacol Res; 2021 Nov; 173():105866. PubMed ID: 34474103
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of cetuximab-containing regimens in the treatment of recurrent/metastatic head and neck cancer after progression to immune checkpoint inhibitors.
    Lai CL; Chen TH; Chang PM; Tai SK; Chu PY; Yang MH
    J Chin Med Assoc; 2022 Jun; 85(6):687-692. PubMed ID: 35507025
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.